Uganda Launches HIV Prevention Drug
Dr Aceng launching the drug on April 17th in Lira
By Patrick Okino
The Government of Uganda, through the Ministry of Health, has officially launched the use of Lenacapavir, a new long-acting HIV prevention drug. This addition will complement existing HIV prevention methods across the country.
The launch ceremony took place at former Akii Bua stadium ground in Lira City on April 17, 2026, and was presided over by Dr. Jane Aceng Ocero, Uganda’s Minister of Health and Member of Parliament for Lira City.
Lenacapavir is an injectable Pre-Exposure Prophylaxis (PrEP) drug that is administered once every six months. Clinical trials have shown that when used as prescribed, Lenacapavir is both safe and highly effective in preventing HIV acquisition.
Dr. Aceng Ocero highlighted that the rollout of Lenacapavir marks a historic milestone in Uganda’s efforts to end AIDS as a public health threat by 2030.
She explained that the drug will be distributed in phases, with high-burden districts being prioritized. The Ministry of Health has already completed training at 103 health facilities nationwide, which will begin the Phase 1 implementation in April. By December 2026, the goal is for 300 health facilities across Uganda to offer Lenacapavir for PrEP.
Mikael Cleverly, the Deputy Head of Mission for the United States, also spoke at the event on behalf of the development partners.
He expressed the importance of the US-Gilead-Global Fund partnership in making Lenacapavir available to high-burden HIV countries, including Uganda.
He also mentioned that the US and Global Fund aim to provide Lenacapavir to three million people in high-burden countries by 2028.
The Director of Lira Regional Referral Hospital, Dr. Andrew Odur, commended the Ministry of Health’s leadership in tackling the HIV burden.
He noted the significant progress in reducing mother-to-child HIV transmission. Dr. Odur also acknowledged concerns from some community members who might mistakenly believe that the introduction of Lenacapavir has solved all HIV-related issues.
He stressed the importance of clear messaging to ensure the drug is used appropriately and effectively.
Dr. Odur also emphasized the need to continue addressing Non-Communicable Diseases (NCDs), noting a concerning rise in cases of conditions like high blood pressure and diabetes, which could complicate efforts to reduce HIV rates. The hospital has already established a wellness clinic to offer services like blood pressure checks and diabetes screenings.
Dr Odur said that awareness and education will be key to ensuring the success of Lenacapavir and the broader fight against HIV in Uganda.
